- Details
- Karim Fizazi discusses the efficacy and safety of darolutamide with Alicia Morgans. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer (nmCRPC). Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. In total, 1509 patien...
|
- Details
- Susan Halabi discusses new findings in the evaluation of racial disparities in progression-free survival across nine trials. Biographies: Susan Halabi Ph.D Professor of Biostatistics and Bioinformatics. Duke Cancer Institute Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinoi...
|
- Details
- Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision. Biographies: Zachary Klaassen, MD, MSc, Urolo...
|
- Details
- (Length of Presentation: 8 minutes) Christopher Wallis presents observational data from a large, population-based matched cohort demonstrating an association between treatment with radiotherapy vs radical prostatectomy and non-prostate cancer mortality. This controversial topic in urologic oncology is a usual subject of interest with respect to comparative effectiveness studies. In observational s...
|
- Details
- (Length of video: 5 min) Tom Keane, MBBCh, FRCSI, FACS provides highlights of the recent press release of ARAMIS, a phase III trial of darolutamide in patients with non-metastatic castrate-resistant prostate cancer. Darolutamide significantly extended metastasis-free survival compared to placebo, meeting its primary endpoint. The safety profile and tolerability of darolutamide observed in the ARAM...
|
- Details
- Charles Ryan and Alicia Morgans discuss the nmCRPC patient population and what is the meaning of the term "nonmetastatic" prostate cancer. They highlight the relevance of meaningful dialogue that should be had with patients to assure the right treatment choice is made. Biographies: Charles J. Ryan, MD Alicia Morgans, MD, MPH
|
- Details
- (Length of Presentation: 9 min) Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity...
|
- Details
- Cora Sternberg highlights from a number of key treatments in GU Oncology in a discussion with Alicia Morgans. Results from the only Phase 3 health-related quality-of-life (HRQoL) analyses in urothelial carcinoma from the KEYNOTE-045 study delivers results for patients who received 2 nd line therapy. A relevant discussion follows on a Phase 2 trial investigating 3 different dosing regimens of radiu...
|
- Details
- (Length of Discussion: 10 min) Michael Cookson, MD, MMHC, talks with Alicia Morgans, MD on the newest developments in the AUA CRPC guidelines incorporating the results of the SPARTAN and PROSPER nmCRPC studies. The intent of this guideline amendment is to update current management of index patient 1: asymptomatic non-metastatic CRPC. Michael shares the need to revamp current guidelines which are s...
|
- Details
- (Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...
|
